November 19th 2024
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung cancer with MET exon 14 skipping alterations eligible for tepotinib.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
The Challenges of Identifying Biomarkers in Lung Cancer
July 18th 2014Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.
Watch
An Analysis of a Phase II study MK-2206 plus Erlotinib in NSCLC
June 12th 2014Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.
Watch
Adding Necitumumab to Standard of Care Improves Survival in Squamous NSCLC
June 11th 2014Adding necitumumab to standard of care with gemcitabine-cisplatin improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) of squamous histology.
Read More
ARAF as a New Driver in Lung Adenocarcinoma
June 9th 2014Luiz H. Araujo, MD, medical oncologist, Corporate Cancer Foundation fellow, Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, discusses the discovery of oncogenic ARAF as a new driver for lung cancer.
Watch
Promise Seen With EGFR Inhibitor CO-1686 in Treatment-Resistant NSCLC
June 2nd 2014The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).
Read More
FDA Grants Breakthrough Therapy Designation for CO-1686 for EGFR T790M-Positive NSCLC
May 21st 2014The EGFR inhibitor CO-1686 has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic T790M mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of EGFR-targeted therapy.
Read More
Immune Checkpoint Inhibitors in NSCLC
May 7th 2014Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the variety of immune checkpoint inhibitors that are currently being explored as treatments for patients with non-small cell lung cancer (NSCLC).
Watch